Clinical Trial Update: The Minimal Effective Volume (MEV90) of Ropivacaine 0.75% for Ultrasound-guided Transmuscular Quadratus Lumborum Block [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating the minimal effective volume (MEV90) of ropivacaine 0.75% for an ultrasound-guided transmuscular quadratus lumborum block in Percu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Stone Disease
• Percutaneous Nephrolithiasis
• Percutaneous Nephrolithotomy Associated Pain
• Renal Calculi

Drugs mentioned

• Ropivacaine 0.75% (Ropivacaine)

Snippet

Sponsor: Zealand University Hospital | Conditions: Percutaneous Nephrolithotomy | Phase 4 | Status: UNKNOWN